Utah Medical Products (UTMD) Amortization of Deferred Charges (2021 - 2026)

Utah Medical Products' Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $15000.0 for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 25.0% year-over-year to $15000.0 in Q1 2026; TTM through Mar 2026 was $59000.0, a 20.41% increase from a year earlier, with the FY2025 full-year figure at $56000.0, up 9.8% from the prior year.
• Amortization of Deferred Charges steadied at $15000.0 in Q1 2026 per UTMD's latest filing, from $15000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $15000.0 in Q3 2025 and bottomed at $12000.0 in Q2 2022.
• The 5-year median for Amortization of Deferred Charges is $13000.0 (2022), against an average of $13411.8.
• Across the five-year window, Amortization of Deferred Charges surged 148.28% in 2022 and slipped 14.29% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $14000.0 in 2022, then changed by 0.0% to $14000.0 in 2023, then decreased by 7.14% to $13000.0 in 2024, then gained by 15.38% to $15000.0 in 2025, then changed by 0.0% to $15000.0 in 2026.
• Per Business Quant, the three latest UTMD Amortization of Deferred Charges figures stand at $15000.0 (Q1 2026), $15000.0 (Q4 2025), and $15000.0 (Q3 2025).